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Introduction
The Coronavirus Disease 2019 (COVID-19) outbreak 
represents a serious public health problem that is 
straining health systems around the world.
As of June 25th, 2020, as many as 9,296,202 cases of 
COVID-19 have been confirmed and 479,133 patients 
have died globally, according to the World Health 
Organization (WHO) [1]. 
In addition to confirmed cases, there are also suspected 
cases of COVID-19 which should be promptly tested 
where possible in order to immediately implement 
isolation measures and trace contacts. In a context of 
uncertainty, since the infection is caused by a new and still 
little understood virus for which no vaccines or specific 
medications are currently available, the recognition of 
clinical signs and symptoms as well as clinical features 
in affected subjects is of vital importance. Severe Acute 
respiratory syndrome Coronavirus  2 (SARS-CoV-2) 
is the latest known virus that has spread worldwide. 
Viruses, particularly RNA viruses, have high mutation 
rates and are characterized by a particularly high 
virulence and transmissibility and can cause more or 
less severe infections. To date, SARS-CoV-2 appears to 
be highly virulent and easily transmissible, it can affect 
many organs of the body and manifest in many ways [2]. 
Applying the lessons learned from past epidemics can 
help us to better address the new challenges. The previ-
ous Coronavirus (CoV) epidemic that hit the world popu-
lation was Severe Acute Respiratory Syndrome (SARS) 
in 2003 which manifested as an atypical pneumonia with 
reported symptoms including fever, dry cough, dyspnea, 
diarrhea and sore throat [3]. The modes of transmission 
and the clinical features of the two infections initially 
seemed to be superimposable. Both infections are trans-
mitted through respiratory droplets or secretions and by 
close person-to-person contact [4]. In some cases, COV-
ID-19 patients do not show the typical signs of respira-
tory infections but have unusual symptoms or only very 
mild symptoms [5]. 
Furthermore, the presence of underlying health condi-
tions increases the risk of developing severe illness [6]. 
Therefore, early recognition of suspected cases through 
the evaluation of clinical and symptomatic characteris-
tics should represent the first tool that can direct towards 
the most appropriate diagnostic and therapeutic strate-
gies and that can help interrupt the chains of transmis-
sion of the virus. 
This review is a comparative analysis of the 
characteristics of the SARS and COVID-19 epidemics 
and summarizes in detail the clinical signs and 
symptoms as well as the comorbidities of subjects with 
SARS and COVID-19, analyzed in studies published 
worldwide to date.
SARS-CoV-2, responsible for the current pandemic, is a novel 
strain of the Coronaviridae family, which has infected humans 
as a result of the leap to a new species. It causes an atypical 
pneumonia similar to that caused by SARS-CoV in 2003. SARS-
CoV-2 has currently infected more than 9,200,000 people and 
caused almost 480,000 deaths worldwide. Although SARS-
CoV-2 and SARS-CoV have similar phylogenetic and pathoge-
netic characteristics, they show important differences in clinical 
manifestations.
We have reviewed the recent literature comparing the character-
istics of the two epidemics and highlight their peculiar aspects. 
An analysis of all signs and symptoms of 3,365 SARS patients 
and 23,280 COVID-19 patients as well as of the comorbidities 
has been carried out. A total of 17 and 75 studies regarding 
patients with SARS and COVID-19, respectively, were included 
in the analysis. The analysis revealed an overlap of some symp-
toms between the two infections. Unlike SARS patients, COVID-
19 patients have developed respiratory, neurological and gas-
trointestinal symptoms, and, in a limited number of subjects, 
symptoms involving organs such as skin and subcutaneous tis-
sue, kidneys, cardiovascular system, liver and eyes.
This analysis was conducted in order to direct towards an early 
identification of the infection, a suitable diagnostic procedure 
and the adoption of appropriate containment measures.
Review
Clinical features of COVID-19 and SARS epidemics.  
A literature review
ANTONELLA ZIZZA1, VIRGINIA RECCHIA1, ALESSANDRA ALOISI2, MARCELLO GUIDO3
1 Institute of Clinical Physiology (IFC), National Research Council (CNR), Lecce, Italy; 2 Institute for Microelectronics  
and Microsystems (IMM), National Research Council (CNR), Lecce, Italy; 3 Laboratory of Hygiene, Department of Biological  
and Environmental Sciences and Technologies, Faculty of Sciences, University of Salento, Lecce, Italy - Inter-University Centre  
of Research on Influenza and other Transmissible Infections (CIRI-IT), Genoa, Italy
Keywords
COVID-19 • SARS-CoV-2 • SARS-CoV • SARS • Clinical features
Summary
A. ZIZZA ET AL.
E14
Virological characteristics
This century has been characterized by the presence of 
several zoonotic coronavirus epidemics spread from 
southern China, which have infected humans as a result of 
genetic recombination that have allowed to make the leap 
to a new species  [7]. Phylogenetic analysis revealed that 
SARS-CoV-2, like Middle East Respiratory Syndrome 
Coronavirus (MERS-CoV) and Severe Acute Respiratory 
Syndrome Coronavirus (SARS-CoV), belongs to the genus 
Betacoronavirus of the Coronaviridae family, exhibiting 
about 79% sequence identity with SARS-CoV and sharing 
the same receptor-binding domain (RBD) structure  [8]. 
The complete genome sequence contains 29,751 bp for 
SARS-CoV [9] and 29,811 bp for SARS-CoV-2 [10]. The 
mutation rate in the SARS-CoV genome is similar to that of 
other coronaviruses and moderate compared to other RNA 
viruses [11], unlike that of SARS-CoV-2 which appears to 
have a higher evolutionary rate estimated (mean 2.15 × 10-
6 subs/site/day corresponding to 7.8 × 10-4 subs/site/year) 
(Tab. I) [12].
Epidemiological characteristics
The first cases of atypical pneumonia of unknown 
etiology of SARS were reported on November 16th, 2002 
in Guangdong Province, China and then spread mainly 
among household contacts and healthcare workers [13]. It 
was only after 300 people became infected and 5 died, on 
February 11th, 2003, that the Chinese Ministry of Health 
informed the WHO of an outbreak of acute respiratory 
syndrome [14]. At the end of February 2003, the infection 
was transmitted to Hong Kong by an infected doctor and 
in a few months the infection spread to other countries 
of the world mainly through intercontinental flights. The 
epidemic spread rapidly to Hong Kong, Taiwan, Singapore 
and Hanoi, mostly related to the movement of people 
during the Chinese New Year holiday season [15]. 
The number of reported cases increased exponentially, 
prompting the WHO to issue a global alert about the 
disease on March 13, 2003 (Tab. I) [14]. 
The outbreak was contained in July 2003 with a total 
of 8,098  cases and 774  deaths in 32  countries, with an 
estimated overall case fatality rate (CFR) estimate of 9.6%. 
In mainland China, the country where the epidemic started 
and where the greatest number of cases was reported, there 
were 5,327 infected people and 349 deaths [16]. 
A number of hospitals in various regions of China were 
designated to treat SARS patients only. The outbreak 
came under control and the number of new cases 
gradually declined. On June 24th, 2003, Beijing was 
removed from the WHO’s list of areas with recent local 
transmission of SARS [15]. 
The country most affected after China was Hong Kong with 
1,755 cases and a mortality rate of 17%. The most affected 
country outside Asia was Canada with 251  cases and 
43 deaths. The European region was slightly affected, with 
33 total cases and one death in France. In Italy, only 4 cases 
have been observed [17]. The epidemic was declared ended 
on July 5th, 2003 [14].
Another global epidemic is currently underway which 
started on December 7th, 2019, the day when the first 
positive COVID-19 case was detected. 
The first cases of pneumonia of unknown origin were found 
in China, connected to those who frequent the wholesale 
market of seafood and wet animals located in Wuhan, in 
the province of Hubei, assuming also in this case a zoonotic 
source [18]. A new coronavirus, named SARS-CoV-2, was 
isolated from the epithelium of these patients. It then spread, 
through person-to-person transmission in family homes 
and hospitals, outside Hubei Province in China to many 
countries across the world. The family of the causative 
agent of this outbreak as well as the country where this 
epidemic started are the same as those of SARS [19]. 
The announcement of this epidemic was provided 
by the Wuhan government to the WHO on January 
3rd, 2020, after the involvement of 27 persons and no 
deaths  [20]. Following a rapid spread in China and 
around the world, on January 30, 2020, the International 
Health Regulations Emergency Committee of the WHO 
declared the outbreak a Public Health Emergency of 
International Concern (PHEIC) [21]. 
About 40 days after the declaration of the global 
emergency, with over 118,000  cases in 114  countries 
and territories worldwide and 4,291 deaths, on 11 March 
2020, WHO announced the state of pandemic (Tab.  I). 
The last time the WHO used the label was on June 11, 
2009 for the H1N1 flu, known as “swine flu”, which 
spread across the world, whereas the 2002-2004 SARS 
outbreak was never declared a pandemic.
Since the end of December 2019 and as of June 25th, 2020, 
the infection has been detected in all countries causing more 
Tab. I. Summary of virological and epidemiological characteristics of 
SARS-CoV and SARS-CoV-2 infections.
Characteristics SARS-CoV SARS-CoV-2
First occurrence 
Nov. 16, 2002 
in Foshan, Guangdong




March 13, 2003 Jan 30, 2020
Pandemic 
declaration (WHO)
- March 11th, 2020
Genome RNA RNA
Length, bp 29,751 29,811
Mutation rate 
RNA
0.80-2.38 × 10-3 
subs/site/year











4.0 days  
(95% CI: 3.6-4.4)
5.1 days  
(95% CI: 4.5-5.8)
R0 2-4 1.4-7.23
Asymptomatic rate 2.3-13% 5-8%
Case fatality rate 9.6% 5.1% 
SARS-CoV: severe acute respiratory syndrome; SARS-CoV-2: coronavirus 
disease-2019; bp: base pairs; R0: basic reproduction number; CI: confi-
dence interval.
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than 9.200.000 confirmed cases and almost 480.000 deaths, 
with an overall CFR estimate of 5.1% (Tab. I). 
At present, in China there are 85,119  confirmed cases 
and 4,647 deaths. The virus initially spread exponentially 
in China and in the Western Pacific Region, exceeding 
100,000 cases. In the last few months, the situation seems 
to have stabilized in China and in other Asian countries 
after weeks of rigid control measures. In the last month, 
new cases have emerged, causing fear of a second 
epidemic wave.
The European Region has exceeded 2,600,000 infections, 
reaching nearly 200,000 deaths, and is currently the 
most affected Region with a higher lethality rate (7.5%). 
America has over 4,600,000 infections and 230,000 deaths, 
followed by the Eastern Mediterranean Region with 
almost 970,000 confirmed cases and 22,000 deaths. 
The countries worst affected in terms of number of 
infected people are the United States of America (USA) 
and the Brazil with 2,329,463 and 1,145,906  cases, 
respectively, followed by the Russian Federation, the 
United Kingdom, Peru e Chile with 613,994, 306,866, 
260,810 and 254,416  cases, respectively  [1]. The 
country with the highest number of COVID-19 deaths 
is the USA where 120,955 have lost their lives, with an 
average lethality of 5.2%. Belgium and United Kingdom 
are currently the worst affected countries in terms of the 
case fatality rate (15.9 and 14.0%, respectively) [1].
Transmission 
Both viruses are transmitted from human to human via 
droplets generated by coughing and sneezing, through 
exposure to fomites and through direct contact of 
mucous membranes (eyes, nose and mouth). 
Whether the infection can be transmitted by the oral 
or conjunctival routes has not yet been demonstrated. 
However, SARS-CoV2 has been detected in tears [22], 
similar to SARS-CoV  [23]. Although there is a low 
prevalence of SARS-CoV-2 in the tear fluid of patients, 
it cannot be excluded that the infection could be 
transmitted via the eyes [24].
The role of fecal-oral transmission for SARS-CoV is still 
unknown. Although some coronaviruses are known to be 
spread by the fecal-oral route [25], there is currently no 
evidence that this mode of transmission plays a key role 
in SARS [3]. There is still limited knowledge regarding 
fecal-oral transmission of SARS-CoV2, although Chen 
Y et al. have demonstrated the presence of SARS-CoV-2 
RNA in the feces of COVID-19 patients suggesting 
that, in addition to respiratory and body contact, fecal-
oral transmission is a potential route for SARS CoV-2 
infection  [26]. In a meta-analysis, SARS-CoV-2 RNA 
was detected in 48.1% of the stool samples derived from 
a cohort of patients with COVID-19 and persisted even 
after respiratory samples were negative (Tab. I) [27]. 
In spite of the fact that the data on intrauterine vertical 
transmission are scarce, there is little, if any, clinical or 
serologic evidence suggestive of SARS-CoV and SARS-
CoV-2 transmission from pregnant mothers to newborn 
infants [28, 29]. Contact with infected droplets on a surface 
can be a source of infection, too [3, 30]. Van Doremalen 
et al. found that SARS-CoV-2 can remain viable and 
infectious in aerosols for 3 hours and on surfaces up to 
days. The stability of this virus is similar to that of SARS-
CoV  [30]. This study has also shown that the virus is 
most stable on plastic and stainless steel with viable virus 
detected up to 72 hours in the absence of any intervention. 
Viruses lose their infectivity after exposure to common 
disinfectants such a Clorox, 75% ethanol and fixatives 
such as formaldehyde and paraformaldehyde  [31,  32]. 
Careful attention should also be paid to asymptomatic 
cases whose role in viral transmission is still controversial. 
During the SARS epidemic, some studies reported the 
absence of asymptomatic cases, while, where reported, 
the incidence of asymptomatic cases corresponded to 13% 
of all SARS-positive cases [33]. The rate of asymptomatic 
or mild infections of COVID-19 ranges between 5 and 
78% (Tab.  I)  [34,  35]. Asymptomatic SARS infection 
was associated with lower SARS antibody titers and the 
transmission from asymptomatic patients appeared to 
play no or only a minor role [33].  
SARS-CoV viral load in upper respiratory tract 
secretions was low in the first 5 days of illness, then 
increased progressively and peaked early in the second 
week, which helped reduce more effectively the infection 
transmission in the first days of illness [36].
In a study, Zou L et al. showed that the viral RNA levels 
in people with COVID-19 appear to be higher soon after 
symptom onset compared with later in the illness [37], 
which suggests that transmission is more likely to occur 
at an earlier stage of infection even when symptoms are 
relatively mild. The high rate of asymptomatic infections 
is often the result of a long incubation period. The median 
incubation period for COVID-19 is estimated to be 
5.1 days, (95% CI: 4.5 to 5.8) [38], slightly longer than 
for SARS-CoV (4.0 days, 95% CI: 3.6-4.4) (Tab. I) [39]. 
The incubation period for SARS in children and adolescents 
was 2-10 days, with a mean of 6.4  days (95% CI: 5.2-
7.7) [39]. The average incubation period for COVID-19 in 
children is 6.5 days (95% CI: 4,6-8,4), with a range from 
2 to 10 days [40]. The interval during which an individual 
with COVID-19 is infectious is still uncertain.
The transmissibility of SARS was determined by a 
basic reproduction number (R0) of approximately 3, 
with values oscillating between 2 and 4, consistent 
with a disease spread by direct contact or larger virus-
laden droplets that travel only a few meters rather than 
by lighter airborne particles [3, 41]. Some studies have 
estimated the mean R0 for COVID-19 to range from 1.4 
to 7.23 (Tab. I) [2]. R0 is used when there is a dynamic 
infectious disease and the population is not vaccinated, 
and it is usually estimated on the basis of the growth 
rate of the number of cases. The estimated values of 
R0 were lower in the early phase of the epidemic. They 
subsequently increased during the other phases of the 
epidemic and then returned to the initial levels [42]. 
Therefore, COVID-19 can be considered as a 
highly transmissible disease compared with SARS. 
Epidemiological factors, such as the ability to recognize 
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the infection at an early stage, the measures of social 
distancing adopted, the access to public health resources 
can cause considerable variations of this parameter.
Pathogenesis and clinical features
SARS-CoV and SARS-CoV2 cause severe acute 
respiratory syndrome and appear to have the same 
pathogenesis. Both viruses use the angiotensin-converting 
enzyme 2 (ACE2) as cell receptor to gain entry into the 
human cells. The infection is triggered by the binding of 
the virus spike protein to ACE2 and causes both upper and 
lower respiratory tract infections [43, 44].
Based on past studies on SARS-CoV, both viruses bind 
to epithelial cells in the nasal cavity and start replicating. 
The viruses then propagate and migrate down the 
respiratory tract along the conducting airways, also 
becoming clinically manifest  [45]. A study reports that 
SARS CoV-2 has higher affinity for binding than SARS 
CoV and this contributes to its more efficient infection of 
humans [46]. About 20% of the infected patients develop 
severe disease. The virus reaches the gas exchange units 
of the lung causing a progressive respiratory failure due 
to alveolar damage, resulting in apoptosis and even cell 
death  [44,  47]. ACE2 receptors are present in the lung 
alveolar cells, but are also expressed in numerous other 
organs, in the enterocytes of the small intestine, as well 
as in the heart, kidney, bile duct, liver, esophagus and 
testicle, and in arterial and venous endothelial cells and 
arterial smooth muscle cells. This tissue distribution of 
ACE2 correlates with the sites of infection and with the 
pathology [43].
Signs and symptoms
SARS is characterized as a viral pneumonia with rapid 
respiratory deterioration  [48]. COVID-19 has many 
clinical features similar to those of SARS but COVID-19 
infection presents with a wide spectrum of severity and 
often with non-specific symptoms. About 80% of patients 
experience no signs or mild symptoms of disease, 14% 
have severe clinical manifestations and only 5% critical 
conditions. Older age and presence of comorbidities 
appear to be important factors associated with clinical 
severity of disease [4].
We analyzed the clinical characteristics reported in 
patients with SARS-CoV and SARS-CoV-2. A total 
of 17 and 75  studies regarding patients with SARS 
and COVID-19, respectively, were included in the 
analysis. Overall, 3,365  patients with SARS-CoV and 
38,318 patients with SARS-CoV-2 were analyzed. 
The results are detailed in Table  II. In the first part of 
the Table, signs and symptoms of 3,365 SARS patients 
and 23,280 COVID-19 patients were considered. This 
analysis revealed an overlap of some symptoms between 
the two infections. SARS-CoV2 infection presents a 
greater variety of symptoms and involves several organ 
systems. SARS-CoV affects a few organs and a limited 
number of symptoms are present in a high percentage 
of the infected subjects. In particular, the most common 
clinical manifestations were systemic [fever (87.90%), 
chills (53.52%), and malaise (49.18%)]. In addition, 
respiratory symptoms [cough (58.31%)], neurological 
symptoms [headache (44.40%)], and musculoskeletal and 
connective symptoms [myalgia (40.62%)] were detected.
SARS-CoV2, on the other hand, preferentially infects 
the cells of the respiratory tract, but it also has high 
affinity for other organs. Therefore, symptomatic 
patients present a greater variety of symptoms affecting 
many organs but in a smaller number of subjects. Typical 
symptoms are respiratory among which cough is the 
most frequent (62.50%). Other frequent symptoms are: 
fever (58.9%), myalgia/arthralgia (35.62%), headache 
(32.48%), shortness of breath/dyspnea (27.46%), and 
diarrhea (18.52%). Unlike SARS patients, COVID-19 
patients have developed numerous other respiratory, 
neurological and gastrointestinal symptoms, and, in 
a limited number of subjects, symptoms involving 
organs such as skin and subcutaneous tissue, kidneys, 
cardiovascular system, liver and eyes.
Comorbidities 
Seventeen studies have been included in the analysis of 
comorbidities and risk factors for a total of 3,365 patients 
with SARS-CoV.
In the 3,365 SARS patients analyzed, the most common 
comorbidities, present in a very low percentage of 
subjects, were diabetes (0.21%), cardiovascular 
disease (0.12%), COPD and chronic liver disease, both 
present in 0.09% of subjects. A total of 72 studies and 
26,650 patients with COVID-19 have also been analyzed. 
The results showed the most prevalent comorbidities 
were hypertension (21.00%) and diabetes (15.37%), 
followed by cardiovascular disease (11.28%). The data 
also showed numerous COVID-19 infected subjects 
with hyperlipidemia (10.20%) or obesity (9.77%). 
Furthermore, diseases of the respiratory system such as 
COPD and asthma were present in 2.57 and 2.26% of 
patients, respectively. Chronic kidney disease was also 
found in 2.02% of patients.
Smoking habits have been reported in 2.75% of patients. 
There are numerous differences in the prevalence of 
comorbidities among the studies analyzed. In one recent 
study conducted, the authors presented the comorbidities 
of 5,700 patients hospitalized for COVID-19 in the New 
York City area. The most common comorbidities were 
hypertension (3,026; 56.6%), obesity (1,737; 41.7%) and 
diabetes (1,808; 33.8 %) [49]. The data are significantly 
different from those obtained in other studies from 
various areas of the world.
Guan WL et al. analyzed the clinical characteristics of 
more than 1,000  patients from mainland China. The 
most common comorbidities were hypertension in 15% 
of patients and diabetes in only 7.4% of patients. No 
other comorbidities were observed in over 2.5% of the 
COVID-19 patients analyzed [50].
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Tab. II. Clinical features of patients with SARS-CoV and SARS-CoV-2 infections.

Characteristics N. of SARS-CoV N. of SARS-CoV-2 
studies % (95% CI) studies % (95% CI) 
Patients, n. 17 3,365 71 23,280 
Gender 
Male, n. (%) 17 1,360 (40.4) 67 6,530 (55.8) 
Female, n. (%) 17 2,005 (59.6) 67 5,179 (44.2) 
Age group 
Children (<18 ys), n. (%) 4 92 (2.7) 15 807 (3.5) 
Adults/Older, n. (%) 14 3,273 (97.3) 55 22,374 (96.5) 
Systemic/General symptoms 
Fever 17 87.90 (86.80-89.01) 71 58.9 (58.23-59.49) 
Fatigue/Malaise 17 49.18 (47.49-50.87) 71 8.91 (8.54-9.27) 
Chills  17 53.52 (51.84-55.21) 71 0.96 (0.84-1.09) 
Influenza-like  17 30.61 (29.05-32.17) 71 - 
Night sweats  17 11.80 (10.71-12.89) 71 - 
Respiratory, thoracic and 
mediastinal symptoms 
Cough 17 58.31 (56.64-59.97) 71 62.50 (61.87-63.12) 
Shortness of breath/Dyspnea 17 26.48 (24.99-27.97) 71 27.46 (26.89-28.03) 
Sputum production 17 26.54 (25.05-28.03) 71 7.32 (6,99-7,65) 
Rhinorrhea/Runny nose  17 2.97 (2.40-3.55) 71 4.90 (4.62-5.18) 
Sore throat 17 21.63 (20.24-23.03) 71 3.69 (3.45-3.94) 
Acute respiratory distress 17 - 71 0.77 (0.41-0.88) 
Nasal congestion/Stuffy nose 17 - 71 0.55 (0.46-0.65) 
Chest pain 17 1.84 (1.39 -2.30) 71 0.34 (0.26-0.41) 
Pharyngeal erythema  17 - 71 0.34 (0.26-0.41) 
Chest distress  17 - 71 0.31 (0.24-0.38) 
Haemoptysis  17 0.68 (0.41-0.96) 71 0.30 (0.23-0.37) 
Tachypnea  17 1.58 (1.15-2.00) 71 0.22 (0.16-0.28) 
Voice hoarse  17 - 71 0.06 (0.03-0.10) 
Coryza 17 15.75 (14.52-16.98) 71 0.03 (0.01-0.05) 
Oropharyngeal pain  17 - 71 0.004 (0.00-0.01) 
Rhonchi 17 1.10 (0.75-1.45) 71 - 
Percussion dullness  17 0.21 (0.05-0.36) 71 - 
Pleurisy 17 0.09 (0.00-0.19) 71 - 
Wheezing 17 0.03 (0.00-0.09) 71 - 
Cardiovascular symptoms 
Cardiac injury 17 - 71 0.12 (0.07-0.16) 
Palpitation 17 2.91 (2.34-3.48) 71 0.12 (0.08-0.17) 
Tachycardia 17 1.96 (1.49-2.34) 71 0.03 (0.01-0.06) 
Shock 17 - 71 0.02 (0.00-0.04) 
Gastrointestinal symptoms 
Diarrhea  17 19.82 (18.47-21.17) 71 18.52 (18.12-19.12) 
Abdominal pain 17 5.65 (4.87.6.43) 71 6.51 (6.19-6.82) 
Vomiting  17 9.30 (8.32-10.28) 71 5.00 (4.72-5.28) 
Nausea 17 13.16 (12.02-14.31) 71 4.63 (4.36-4.90) 
Anorexia 17 24.07 (22.63-25.52) 71 1.40 (1.25-1.56) 
Dehydration  17 - 71 0.03 (0.01-0.05) 
Neurological symptoms 
Headache 17 44.40 (42.72-46.08) 71 32.48 (31.88-33.08) 
Ageusia 17 - 71 1.89 (1.72-2.07) 
Dizziness 17 20.48 (19.11-21.84) 71 0.37 (0.30-0.45) 
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
Anosmia 17 - 71 0.34 (0.26-0-41) 
Impaired consciousness  17 - 71 0.27 (0.20-0.33) 
Agitation 17 - 71 0.17 (0.12-0.23) 
Corticospinal tract signs 17 - 71 0.17 (0.11-0.22) 
Dysexecutive syndrome  17 - 71 0.06 (0.03-0.09) 
Perfusion abnormalities  17 - 71 0.05 (0.02-0.08) 
Acute cerebrovascular disease 17 - 71 0.04 (0.01-0.06) 
Guillain-Barré syndrome (GBS) 17 - 71 0.03 (0.01-0.05) 
Leptomeningeal enhancement 17 - 71 0.03 (0.01-0.06) 
Nerve pain 17 - 71 0.02 (0.00-0.04) 
Seizure 17 0.03 (0.00-0.09) 71 0.01 (0.00-0.03) 
Ataxia 17 - 71 0.004 (0.00-0.013) 
Miller Fisher Syndrome 17 - 71 0.004 (0.00-0.013) 
Polyneuritis cranialis 17 - 71 0.004 (0.00-0.013) 
Anxiety 17 0.03 (0.00-0.09) 71 - 
Kidney symptoms 
Dialysis 17 - 71 0.15 (0.10-0.21) 
Kidney injury  17 . 71 0.11 (0.07-0.15) 
Musculoskeletal  
and connective symptoms 
Myalgia/arthralgia 17 40.62 (38.96-42.28) 71 35.62 (35.00-36.23) 
Hypodynamia  17 - 71 0.25 (0.19-0.32) 
Back discomfort 17 - 71 0.01 (0.00-0.03) 
Rigor  17 19.17 (17.84-20.50) 71 - 
Neck pain 17 0.09 (0.00-0.19) 71 - 
Skin and subcutaneous 
tissue symptoms 
Itch  17 - 71 0.91 (0.79-1.04) 
Maculopapular rash 17 - 71 0.76 (0.64-0.87) 
Urticaria 17 - 71 0.33 (0.25-0.40) 
Pseudo-chilblains 17 - 71 0.30 (0.23-0.38) 
Chickenpox-like vesicles  17 - 71 0.15 (0.10-0.20) 
Pain  17 - 71 0.14 (0.09-0.19) 
Livedo/necrosis 17 - 71 0.09 (0.05-0.13) 
Erythematous rash 17 - 71 0.07 (0.04-0.25) 
Burning 17 - 71 0.09 (0.06-0.13) 
Rash  17 00.3 (0.00-0.09) 71 0.02 (0.00-0.04) 
Cyanosis 17 - 71 0.004 (0.00-0.013) 
Eye symptoms 
Conjunctival congestion 17 - 71 0.05 (0.02-0.08) 
Vision impairment 17 - 71 0.01 (0.00-0.03) 
Hepatic symptoms 
Liver injury 17 - 71 0.37 (0.29-0.45) 
. 
Comorbidities and risk factor 
Characteristics N. of SARS-CoV N. of SARS-CoV-2 
studies % (95% CI) studies % (95% CI) 
Patients, n. 17 3,365 72 26,650 
Gender 
Male, n. (%) 17 1,360 (40.4) 68 15,163 (58.3) 
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Female, n. (%) 17 2,005 (59.6) 68 10,860 (41.7) 
Cardiovascular diseases 17 0.12 (0.00-0.24) 72 11.28 (10.90-11.66) 
Hypertension 17 0.03 (0.00-0.09) 72 21.00 (20.51-21.49) 
Cardiac arrhythmia 17 - 72 1.14 (1.01-1.27) 
Coronary artery disease 17 - 72 6.43 (6.13-6.72) 
Congestive heart failure 17 - 72 2.29 (2.11-2.47) 
Cerebrovascular disease 17 0.03 (0.00-0.09) 72 0.89 (0.78-1.01) 
Respiratory system diseases 17 - 72 0.58 (0.49-0.67) 
Asthma  17 - 72 2.26 (2.08-2.44) 
COPD 17 0.09 (0.00-0.19) 72 2.57 (2.38-2.76) 
Chronic lung disease 17 - 72 0.81 (0.71-0.92) 
Nervous system disease 17 - 72 0.36 (0.29-0.43) 
Chronic kidney disease 17 0.06 (0.00-0.14) 72 2.02 (1.85-2.19) 
End-stage kidney disease  17 - 72 0.70 (0.60-0.80) 
Chronic liver disease 17 0.09 (0.00-0.19) 72 0.67 (0.57-0.67) 
Cirrhosis  17 - 72 0.15 (0.10-0.20) 
Hepatitis B 17 - 72 0.14 (0.10-0.19) 
Hepatitis C 17 - 72 0.01 (0.00-0.02) 
Tuberculosis 17 - 72 0.04 (0.02-0.07) 
Digestive system disease 17 - 72 0.54 (0.46-0.63) 
Hyperlipidaemia  17 - 72 10.20 (9.84-10.56) 
Hypercholesterolemia 17 - 72 0.71 (0.61-0.81) 
Obesity  17 - 72 9.77 (9.41-10.13) 
Diabetes  17 0.21 (0.05-0.36) 72 15.37 (14.93-15.80) 
Endocrine system disease  17 - 72 0.51 (0.42-0.60) 
Rheumatologic disease 17 - 72 0.02 (0.00-0.04) 
Immunosuppression 17 - 72 1.09 (0.96-1.21) 
HIV infection 17 - 72 0.18 (0.13-0.23) 
Transplant 17 - 72 0.22 (0.16-0.27) 
Blood disorder 17 - 72 0.04 (0.01-0.06) 
Myelodysplastic syndrome  17 0.06 (0.00-0.14) 72 - 
Malignancy 17 0.03 (0.00-0.09) 72 2.22 (2.04-2.39) 
Allergic rhinitis 17 - 72 0.39 (0.32-0.47) 
Hyoxemia 17 - 72 0.02 (0.00-0.03) 
Pregnancy 17 - 72 0.03 (0.01-0.05) 
Smoking  17 - 72 2.75 (2.55-2.95) 
Prognosis 
Characteristics N. of SARS-CoV-1 N. of SARS-CoV-2 
studies % (95% CI) studies % (95% CI) 
Patients, n. 17 3,365 75 38,318 
Gender 
Male, n. (%) 17 1,360 (40.4) 71 15,532 (58.1) 
Female, n. (%) 17 2,005 (59.6) 71 11,215 (41.9) 
Prognosis 
Hospital admission 17 55.66 (53.98-57.34)*  73 91.60 (91.17-91.83)* 
Discharge 17 91.41 (90.46-92.36)*  65 52.53 (51.92-53.15)* 

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Prognosis 
Of the 3,365 patients hospitalized for SARS-CoV and 
the 38,318 patients hospitalized for SARS-CoV-2 that 
were included in our analysis, 55.66% and 91.60%, 
respectively, were admitted to hospital. 
At the time the reports were written, 91.41% of patients 
hospitalized for SARS-CoV and only 52.53% of patients 
with SARS-CoV-2 were discharged. 
Based on data from 17 studies on SARS and 72 studies on 
COVID-19, the percentage of deaths stood at 5.26% and 
7.80% for SARS-CoV and SARS-CoV-2, respectively.
Diagnostic tests
The 2003 pandemic of SARS profiled the ability of 
modern diagnostic microbiology and molecular biology 
to identify, isolate and characterize, within weeks, a 
previously unknown virus. On 10 April 2003, quantitative 
TaqMan-format assay for SARS-associated coronavirus 
was published for the first time [51]. Diverse protocols 
were proposed within the different molecular testing 
approaches over time. Most conventional polymerase 
chain reaction (PCR) assays were designed with the Orf1b 
or nucleoprotein gene for nucleic acid amplification, 
and SYBR Green based PCR protocol was reported as a 
benefit to screen samples with sequence variations in the 
virus [52]. Also, monoclonal antibodies or monospecific 
polyclonal antibody directed to the nucleocapsid (N) 
protein were found to be a sensitive and specific test 
for antigen detection; however, most of these rapid tests 
have never been exhaustively investigated in prospective 
cohort studies owed to the short-lived epidemic [48]. 
Given the current epidemiology and the high risk of 
transmission, the rapid and accurate identification of the 
infection is crucial for effective COVID-19 containment. 
At writing time, real-time PCR molecular assays for 
detecting SARS-CoV-2 in respiratory specimens are the 
current reference standard for infection diagnosis. The 
technique is generally very sensitive and specific and 
may be used for routine diagnostics of COVID-19 [53]. 
However, Yong and colleagues showed the 
ineffectiveness of real-time PCR as the only diagnostic 
test due to its inability to detect previous infections 
highlighting the importance of using serological tests 
as well [54]. Where epidemiological information warns 
people might have been node of disease transmission, 
but they had recovered from sickness, SARS-CoV-2 
IgG serology allows establishing past infection. In 
addition, if carried out within the correct timeframe after 
symptoms onset, serology assays can detect both active 
and past infections  [55]. Remarkably, the importance 
of serological tests for epidemiological investigation 
of COVID-19 cases rapidly emerged in a much more 
pressing way than in SARS full epidemic happened. 
At the end of April 2003, tests to detect antibodies 
produced in response to the SARS coronavirus infection 
are under development but not still commercially 
available. ELISA (Enzyme Linked ImmunoSorbant 
Assay) test for the detection of IgM and IgG antibodies 
in serum produced positive results reliably after 21 from 
the onset of the disease and IFA (Immunofluorescence 
Assay) test for the detection of IgM produced positive 
results after about 10 days of illness [56].
Later studies revealed that specific serum antibodies against 
whole SARS-CoV by indirect immunofluorescence or 
neutralization tests starts to appear at about day 7 and, 
while IgM were not detectable after 2 to 3 months, IgG 
maintained for over one year [57]. 
The titer of neutralizing antibodies peaked from 20 to 30 
days after infection and was sustained for a long time in 
those who survived, while the neutralizing antibody level 
of those who died peaked at day 14 and then gradually 
diminished [58].
In these months, a flood of novel rapid serologic 
immunoassays designs as long as point-of care 
technologies are proposed, and a lot of them are 
commercially available. Despite the considerable 
role they play, some evidences suggest that many kits 
currently available are not adequately accurate  [59] 
and several challenges remain, to which we must pay 
attention. Recognizing the disease, during the acute 
phase of infection, needs high sensitivity and specificity; 
cross-reactivity with other viral agents should be 
weighed; antibody kinetics over time must also be 
investigated, to determine thresholds of immunity [60]. 
Both these testings, molecular and serological, are 
expected to support welfare decision-makers about 
measures to contain the outbreak.
Containment measures
During an unpredictable and unprecedented pandemic 
such as that caused by COVID-19, anxiety and 
stress  –  often boosted by the media as well as by the 
political decisions themselves  –  alter how people 
perceive new diseases and their consequent actions. 
Moreover, whenever decision-making involves risks, 
individuals can become irrational in several dysfunctional 
ways [61]. Consequently, the ideal approach to improve 
decision-making and crisis management should be 
reducing anxiety and stress through rapid diagnosis [62] 
Death 17 5.26 (4.51-6.01)* 72 7.80 (7.48-8.12)* 
. 
* At the time of writing reports; for clinical features: 4 studies do not report gender differences, 1 study do not report age group;
for comorbidities: 4 studies do not report gender differences; for prognosis: 2 studies do not report hospital admission, 10 
studies do not report discharge, 3 studies do not report death. 
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and specific antiviral treatments. However, in the real 
world, most countries are usually unprepared to face 
such a pandemic. In particular, during COVID-19, an 
initial lack of positive control, primers and/or probes 
as long as a lack of personnel/time and of specific 
therapies together with a large number of pauci-
symptomatic and asymptomatic people yielded most 
policies to shift towards lockdown measures rather 
than modern laboratory-based testing and consequent 
quarantine  [62,  63]. European countries, for instance, 
implemented a series of containment measures, ranging 
from lockdown to an intermediate safe distancing (Italy, 
France, Spain, Denmark, Norway, Switzerland, Austria, 
Belgium, UK and Germany), with only one country 
that has chosen not to adopt lockdown (Sweden) [64]. 
Most States in the world added in an unprecedented way 
lockdown measures to the other traditional containment 
measures adopted during the last epidemics, such as 
SARS  [65]. However, this widespread governance 
resolution generated new research challenges. Currently, 
scientific and political institutions do not require any 
type of comparative study on the risks and benefits 
before implementing lockdown measures. This happens 
despite the consequences of these old measures to the 
overall mental and physical health of the population’s 
remain mostly unexplored [66].
Conclusions
COVID-19 and SARS are infections with similar 
phylogenetic and pathogenetic characteristics that 
primarily affect the respiratory and gastrointestinal 
systems. The knowledge acquired so far has allowed 
us to highlight some distinctive features of COVID-19 
in comparison to SARS. SARS has a high prevalence 
of severe illness but with a low infectivity in the first 
days of illness, before the development of severe 
illness. Conversely, COVID-19 can be considered as a 
disease with a lower lethality rate but with high risk of 
transmission compared to SARS even in the presence of 
mild symptoms or in the absence of any visible signs of 
infection.
A rather high percentage of SARS patients had typical 
symptoms such as fever, cough, chills, headache, fatigue 
and myalgia. Among the most common symptoms 
in COVID-19 patients are cough, fever, myalgia, and 
headache, but there is no highly prevalent symptom such 
as fever that was detected in almost 90% of the SARS 
patients analyzed. Gastrointestinal and cardiovascular 
symptoms seem to be more common in SARS. Based on 
reports of more than 23,000 COVID-19 cases, numerous 
other less common and atypical manifestations 
including neurological symptoms (ageusia, anosmia), 
dermatologic manifestations and ocular symptoms, have 
also been identified. In light of this, the detection of 
fever, cough and shortness of breath as an identification 
method should be reviewed. In addition, COVID-19 
patients exhibit a wide range of comorbidities. Therefore, 
it is very important to know what signs and symptoms to 
look out for and recognize and which diagnostic tests 
to use for prompt treatment and prevention of further 
infections.
If clinical manifestations are mild and there is no need 
to seek medical care, it is very important that symptoms 
are monitored and national public health measures 
are followed in order to control the spread of the first 
epidemic wave in the countries where it is still in place 
or prevent a further wave of COVID-19.
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